Serum levels of soluble CD163 correlate with the inflammatory process in coeliac disease

A. Daly, C. Walsh, C. Feighery, U. O'Shea, J. Jackson, A. Whelan

Research output: Contribution to journalArticlepeer-review

Abstract

Backgound: In coeliac disease, following the introduction of a gluten-free diet, monitoring mucosal disease activity requires repeated small intestinal biopsies. If a test measuring a circulating inflammatory marker was available, this would be clinically valuable. Aim: To determine if levels of soluble CD163, a scavenger receptor shed by tissue macrophages, correlated with the inflammatory lesion in coeliac disease. Methods: Serum samples were collected from 131 patients with untreated coeliac disease, 40 patients with treated coeliac disease, 92 non-coeliac disease control subjects and 131 healthy controls. A capture enzyme linked immunosorbance assay was established to measure levels of soluble CD163 in sera. The extent of the histological lesion in coeliac biopsies was assessed using a Marsh grading system. Results: Levels of CD163 in untreated coeliac subjects were significantly elevated when compared with the treated coeliac patients, the disease control group and the healthy control subjects (P < 0.0001 in each instance). Moreover, coeliac patients with the most marked histological lesion (Marsh 3) had significantly higher levels of soluble CD163 than patients with Marsh grade 2 lesions (P < 0.0004), with grade 1 lesions (P < 0.0001) and grade 0 lesions (P < 0.0001). Conclusions: Measurement of soluble CD163 may be a useful method of monitoring the inflammatory lesion in coeliac disease.

Original languageEnglish
Pages (from-to)553-559
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume24
Issue number3
DOIs
Publication statusPublished - Aug 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'Serum levels of soluble CD163 correlate with the inflammatory process in coeliac disease'. Together they form a unique fingerprint.

Cite this